M&A

Pfizer has decided to split into three after it failed to sell its consumer healthcare business a few

Pfizer splits into three after failing to sell consumer unit

https://pharmaphorum.com/news/pfizer-splits-into-three-after-failing-to-sell-consumer-unit/

M&A/ News/ News/ Oncology/ Top stories

Nektar, BioMarin, and Alnylam top list of biotech M&A targets

Richard Staines Alnylam, BioMarin, M&A, Nektar Therapeutics 0 Comment

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according

Nektar, BioMarin, and Alnylam top list of biotech M&A targets

https://pharmaphorum.com/news/nektar-biomarin-and-alnylam-top-list-of-biotech-ma-targets/

M&A/ News/ News/ Sales and Marketing/ Top stories

Takeda to cut IT, marketing and sales jobs after Shire merger

Richard Staines M&A, R&D, Rare diseases, Shire, Takeda 0 Comment

Takeda aiming for $1.4bn savings per year

Takeda to cut IT, marketing and sales jobs after Shire merger

https://pharmaphorum.com/news/takeda-to-cut-it-marketing-and-sales-jobs-after-shire-merger/

M&A/ News

Takeda takes biggest gamble of 2018 with Shire merger

Richard Staines M&A, Shire, Takeda 0 Comment

Takeda and Shire have agreed on the remaining terms of their £46 billion merger, creating one of the

Takeda takes biggest gamble of 2018 with Shire merger

https://pharmaphorum.com/news/takeda-biggest-gamble-of-2018-with-shire-merger/

M&A/ News/ UK & Europe/ US

Shire recommends Takeda’s £46bn bid

Richard Staines M&A, Shire, Takeda 0 Comment

Takeda’s shares sharply as mega-merger edges closer

Shire recommends Takeda’s £46bn bid

https://pharmaphorum.com/news/shire-recommends-takedas-46bn-bid/

M&A/ News/ Top stories/ UK & Europe

Takeda woos Shire shareholders with increased bid

Richard Staines M&A, Shire, Takeda 0 Comment

Fourth and probably final bid has increased cash component

Takeda woos Shire shareholders with increased bid

https://pharmaphorum.com/news/takeda-woos-shire-shareholders-with-increased-bid/

M&A/ News/ News/ Oncology

Allergan says not interested in buying Shire

Richard Staines M&A, Rare diseases, Shire, Takeda 0 Comment

Allergan has said it is not interested in buying Shire after all, after announcing yesterday that it was

Allergan says not interested in buying Shire

https://pharmaphorum.com/news/allergan-says-not-interested-in-buying-shire/

M&A/ News

P&G buys Merck KGaA’s consumer health unit for $4.2bn

Richard Staines M&A, Merck KGaA, OTC 0 Comment

Merck KGaA is to sell its consumer health business to Procter and Gamble for $4.2 billion, continuing the

P&G buys Merck KGaA’s consumer health unit for $4.2bn

https://pharmaphorum.com/news/pg-buys-merck-kgaas-consumer-health-unit-4-2bn/

M&A/ News/ News/ Oncology

Shire’s $2.4bn oncology sell-off seen as Takeda spoiler

Richard Staines M&A, Oncology, Servier, Shire, Takeda 0 Comment

Move seen as attempt to fend off Takeda takeover

Shire’s $2.4bn oncology sell-off seen as Takeda spoiler

https://pharmaphorum.com/news/shire-sell-cancer-business-servier-2-4bn/

1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

M&A

Login